Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
Recruiting · NCT05918861 · Registry updated 2026-06-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | acute coronary syndrome, cardiovascular disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Phase 3 | 2026-06-22 | NCT05918861 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| DalCor Pharmaceuticals | 1 |
| The Montreal Health Innovations Coordinating Center (MHICC) | 2 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||